This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Echavarría, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Echavarría, M.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, October 2008, p. 704-715, Vol. 21, No. 4
0893-8512/08/$08.00+0     doi:10.1128/CMR.00052-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Adenoviruses in Immunocompromised Hosts

Marcela Echavarría*

Clinical Virology Laboratory, Centro de Educación Médica e Investigaciones Clínicas (CEMIC) University Hospital, Buenos Aires, Argentina

Summary: The number of patients with acquired immunodeficiency has grown steadily as a result of both a larger number of patients receiving solid organ and hematopoietic stem cell transplants and their longer survival times. The use of newer, more potent immunosuppressive regimens has increased the frequency of severe adenovirus infections. Human adenoviruses are a large group of viruses, represented by at least 52 serotypes with various genotypes divided into genomic clusters, and these may cause a broad variety of clinical manifestations. The development of molecular methods has increased the sensitivity and rapidity of adenovirus infection diagnosis. The implementation of PCR assays has significantly contributed to the identification of patients with disseminated adenovirus disease. More recently, the development of real-time PCR assays has permitted virus quantification and patient follow-up. There is no treatment for adenovirus with demonstrated efficacy, although cidofovir is widely used. Sensitive diagnostic tests for adenovirus can contribute to the early diagnosis and successful treatment of life-threatening adenovirus infections, especially in complex immunocompromised patients. The development of improved adenovirus therapy still remains a challenge. Adenovirus genetic diversity should be considered for diagnosis, typing, and therapeutic interventions.

* Mailing address: Clinical Virology Laboratory, Centro de Educación Médica e Investigaciones Clínicas (CEMIC) University Hospital, Galvan 4102 (C1431FWO), Buenos Aires, Argentina. Phone: (5411) 4546-8228. Fax: (5411) 4541-3790. E-mail: mechavarria{at}cemic.edu.ar

Clinical Microbiology Reviews, October 2008, p. 704-715, Vol. 21, No. 4
0893-8512/08/$08.00+0     doi:10.1128/CMR.00052-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gralinski, L. E., Ashley, S. L., Dixon, S. D., Spindler, K. R. (2009). Mouse Adenovirus Type 1-Induced Breakdown of the Blood-Brain Barrier. J. Virol. 83: 9398-9410 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»